Vodpod videos no longer available.
Celgene announced that it expects its blood cancer medicines, long the core of its business (Revlimid, Thalomid & Vidaza), to bring in $6 billion by 2015. Beyond the earliest product approvals which sparked its ascension, the company says a new psoriasis treatment could easily exceed $2-3 billion per year in revenue. Finally, CEO Sol Barer speaks to CNBC about the future & early progress in developing a stem cell treatment for Crohn’s disease.
The rise to dominance in the biotechnology industry continues for Celgene, a company that was not in the discussion with Amgen, Genentech, Chiron & Immunex less than ten years ago.
Beaker's Blog 
[…] Celgene: the new “big kid” on the block. […]